Researchers at ETH Zurich have developed an implantable device, ECHO, that can lower blood sugar levels in mice with Type 2 diabetes within an hour by converting excess glucose into a harmless acid excreted in urine, WELT reported.
The Science Behind the Implant
The ECHO (Electrocatalytic Closed-Loop Health Optimization) device is a blood sugar-degrading electrical catalyst implanted into the body. It uses a graphite felt with tiny gold and platinum structures; when an electrical current flows, it triggers a chemical reaction that converts excess glucose in the blood into gluconate. This substance is then excreted through the kidneys. Unlike previous research, this system operates without living cells or enzymes. The device only activates when a connected glucose sensor detects high blood sugar, typically worn on the upper arm and linked via Bluetooth to a smartphone or smartwatch. The reaction stops automatically once blood sugar levels return to a safe range.
🚨 This could be the end of Type 2 diabetes. Researchers at ETH Zurich led by Martin Fussenegger built a small wireless implant that uses electricity to break down extra sugar in the blood. It switches off when levels are normal — and means people won’t need diabetes drugs… pic.twitter.com/90ybtxIRA5
“For decades, we have treated diabetes by telling the body how to handle glucose. Now we are showing that we can control glucose directly, with electronics instead of medication,” explained Martin Fussenegger, Professor at ETH Zurich’s Department of Biosystems Science and Engineering in Basel. The team’s findings were published in the journal “Science” on October 22, 2026.
Implant Removes Excess Sugar from Blood
- ECHO is an implant that uses electricity to turn excess blood sugar into a harmless substance passed out in urine.
- It works automatically, turning on only when your blood sugar gets too high, and turning off once it’s normal.
- The device has only been tested in mice so far; it is not yet approved or available for humans.
Preclinical Results in Mice
The ETH Zurich team first tested the ECHO system in five liters of glucose-rich fluid, approximating the blood volume of an adult human. They then tested the implant on overweight mice with Type-2 diabetes. Within 60 to 90 minutes, the device successfully lowered elevated blood sugar to normal levels. During a six-week treatment period, the mice also lost weight, and some of their blood fat values improved. The automatic control system was successfully tested over a 12-day period.
Professor Fussenegger emphasized the safety of the low-voltage system: “Our experiments have shown that neither electrical nor thermal effects cause tissue damage.” The device operates at a very low voltage of around 0.7 to 0.75 volts and 10 milliamps, which the researchers found to be safe in the animal models. Hypoglycemia (dangerously low blood sugar) did not occur during the trials, and no ketoacidosis—a serious complication of diabetes—was observed.
Clinical and Regulatory Hurdles Remain
Andreas Birkenfeld, an independent diabetologist at the University Hospital Tübingen, told the Science Media Center Germany, "I find that a really exciting approach." Humans have a much larger blood volume and therefore more glucose that would need to be converted.
Can an Implant Lower Blood Sugar With Electricity? Researchers at ETH Zurich have developed a small electronic implant that could offer a new way to manage type 2 diabetes. The device, called ECHO, uses an electrically powered catalyst to convert excess glucose into gluconate,… pic.twitter.com/Uk10PFIPeN
The long-term implications of removing glucose from the body are also unknown. Birkenfeld pointed out that there is a risk of blood acidification through ketone bodies or lactate, for example in people with advanced diabetes or kidney damage. Other potential concerns include infections during implantation or technical replacement, an outage of the electrical unit or automatic regulation, and allergic reactions.
Siegfried Ussar, Director of the Adipocyte and Metabolism Department at the Helmholtz Center Munich, noted that the precise electronic control is a significant innovation. “Unlike the unregulated inhibitor approach, this device can theoretically be controlled precisely,” he stated. However, he stressed that the implant cannot be used as a standalone therapy, as it does not address the underlying insulin deficiency.
Global Context and Future Prospects
The global prevalence of diabetes shows the urgency of new treatments. According to the World Health Organization, the number of people living with diabetes worldwide rose from 200 million in 1990 to 830 million in 2022. In Germany, over ten percent of adults have Type-2 diabetes, with approximately 450,000 new cases diagnosed each year. The disease is driven by factors like obesity, lack of exercise, and genetic predisposition.
The ECHO system is classified as a medical product, which could mean a potentially faster regulatory approval pathway compared to new drugs. Fussenegger offered a cautious prognosis: “An exact time frame is tricky, but it shouldn’t take ten years. The hope is for two to five years.” However, he acknowledged that statistically, about 90 percent of all therapeutic approaches that are successful in laboratory animals fail to translate to humans.
This could be the end of Type 2 diabetes. Researchers at ETH Zurich led by Martin Fussenegger built a small wireless implant that uses electricity to break down extra sugar in the blood. pic.twitter.com/oUUtjVTIU4
| Parameter | ECHO Implant (Mouse Study) | Current Standard Care |
|---|---|---|
| Onset of Action | 60-90 minutes | Minutes to hours (depends on medication) |
| Weight Change | Up to 10% loss over 6 weeks | Variable; some medications cause weight gain |
| Primary Mechanism | Electrochemical conversion of glucose to gluconate | Insulin stimulation or medication-induced glucose excretion |
| Reported Side Effects | No hypoglycemia or ketoacidosis in trials | Risk of hypoglycemia, weight gain, gastrointestinal issues |
Consult Doctor for Severe Hyperglycemia
Individuals with pre-existing kidney disease may be at higher risk due to the increased excretion of gluconate. People with a history of severe ketoacidosis or those with advanced insulin deficiency would require extensive study before being considered candidates. Anyone experiencing symptoms of severe hyperglycemia, such as excessive thirst, frequent urination, unexplained weight loss, or fatigue, should consult a healthcare provider for proper diagnosis and management of their diabetes.
Implant Offers New Diabetes Treatment Approach
The ECHO implant represents a novel approach to managing Type-2 diabetes by directly removing excess glucose from the bloodstream. Its success in preclinical trials is a significant scientific achievement, but the path to human application is long. As the research team at ETH Zurich works to develop the device into a medical product, the scientific and medical communities will be watching closely. For now, established treatments like diet, exercise, and medication remain the standard of care for managing this widespread and complex metabolic disease.
🧬 BREAKTHROUGH: Scientists at ETH Zurich have developed a USB-sized electronic implant that converts excess blood glucose into gluconate, which the body excretes in urine. Tested in diabetic mice, the device controlled blood sugar without drugs or insulin for 6 weeks. Human… pic.twitter.com/sK22t5h6Vt
References
- World Health Organization. (2022). “Global report on diabetes.”
- International Diabetes Federation. (2025). “8th Edition of the Diabetes Atlas.”
